Eculizumab to Treat Posterior Reversible Encephalopathy Syndrome Due to Underlying Transplant-Associated Thrombotic Microangiopathy in Patients Receiving Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease

Pre-existing endothelial dysfunction and vascular injury sustained during allogeneic hematopoietic stem cell transplantation (HCT) increases risk for endothelial injury-related complications like posterior reversible encephalopathy (PRES) and transplant-associated thrombotic microangiopathy (TA-TMA) in patients with sickle cell disease (SCD). Herein, we report two SCD HCT recipients in whom PRES-related symptoms resolved only after eculizumab therapy was initiated for underlying TA-TMA.

Source: Biology of Blood and Marrow Transplantation - January 31, 2019 Category: Hematology Authors: Nabanita Bhunia, Rolla Abu-Arja, Rajinder P.S. Bajwa, Jeffery J. Auletta, Hemalatha G. Rangarajan Tags: 189 Source Type: research